title: Centrally applied atrial natriuretic factor diminishes bile secretion in the rat.
abstract: Little is known about the role of centrally applied peptides in the regulation of bile secretion. We previously reported that the intravenous injection of atrial natriuretic factor (ANF) reduces bile acid dependent flow without affecting portal venous pressure in the rat. In the present work, we studied the effects of centrally applied ANF on bile secretion and the possible pathways involved. Rats were cannulated in the brain lateral ventricle for the administration of 1, 10 and 100 ng/microl ANF. After 1 week, the common bile duct was cannulated and bile samples were collected every 15 min for 60 min after the administration of ANF. The excretion rate of various biliary components was assessed. Bile secretion experiments were also performed after bilateral truncal vagotomy or atropine administration to evaluate the participation of a vagal pathway. In addition, the role of the sympathetic system was addressed by combined administration of propranolol and phentolamine. Centrally applied ANF did not modify blood pressure but diminished bile flow and bile acid output. It also reduced sodium and potassium secretion but did not modify protein or phospholipid excretion. Neither bilateral truncal vagotomy nor atropine administration abolished ANF response. Furthermore, combined administration of adrenergic antagonists did not alter ANF inhibitory effect on bile flow. In conclusion, centrally applied ANF reduced bile acid dependent flow not through a vagal or adrenergic pathway in the rat, suggesting the involvement of a peptidergic pathway.
authors.affiliation: Cátedra de Fisiopatología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, 5 Piso, 1113, Buenos Aires, Argentina. lbianc@ffyb.uba.ar
authors.forename: L G
authors.initials: LG
authors.lastname: Bianciotti
authors.forename: M S
authors.initials: MS
authors.lastname: Vatta
authors.forename: C
authors.initials: C
authors.lastname: Vescina
authors.forename: V
authors.initials: V
authors.lastname: Trippodi
authors.forename: M E
authors.initials: ME
authors.lastname: Sabbatini
authors.forename: B E
authors.initials: BE
authors.lastname: Fernandez
mesh_terms: D018674:Adrenergic Antagonists / Q000494:pharmacology; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage* / Q000494:pharmacology*; D001285:Atropine / Q000494:pharmacology; D001646:Bile / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D007276:Injections, Intraventricular; D008297:Male; D010646:Phentolamine / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012964:Sodium / Q000378:metabolism; D013997:Time Factors; D014628:Vagotomy
chemical_list: D018674:Adrenergic Antagonists; C472610:atrial natriuretic peptide, rat; D001285:Atropine; D009320:Atrial Natriuretic Factor; D012964:Sodium; D011433:Propranolol; D011188:Potassium; D010646:Phentolamine